FAQs

Here are frequently asked questions about UDENYCA and biosimilars.

UDENYCA is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low blood cell count.

Biosimilars are FDA-approved biologic medicines that are highly similar to an existing biologic product (known as the reference product) and have no clinically meaningful differences in safety, effectiveness, or quality.

Biologics are medicines made from living cells, such as proteins or antibodies. A biosimilar is developed to work the same way as the reference product.

Because biosimilars offer additional treatment options, they may help increase choice, access, and affordability for patients.

Chemotherapy works by targeting cancerous cells. It can also affect and lower healthy cell counts, including the white blood cells that fight infections.

Do not take UDENYCA if you have had a serious allergic reaction to human G-CSFs, such as pegfilgrastim or filgrastim products.

Before you receive UDENYCA, tell your healthcare provider about all of your medical conditions, including if you have a sickle cell disorder, have kidney problems, are pregnant or plan to become pregnant (it is not known if UDENYCA will harm your unborn baby), are breastfeeding or plan to breastfeed (it is not known if UDENYCA passes into your breast milk).

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of UDENYCA are pain in the bones, arms, and legs. These are not all the possible side effects of UDENYCA. Talk with your healthcare provider about any other side effects. Be sure to review the Patient Information for more side effect information.

UDENYCA provides 3 administration options so your healthcare provider can prescribe the one that meets your individual needs. See your options.

Depending on the administration your healthcare provider prescribes, you may need to return to the office or hospital the day after chemotherapy to receive UDENYCA. Talk to your healthcare provider about which administration option may be right for you.